GoBroad Healthcare Group (GHG), a leading research-oriented medical institution in China, has established ourselves as a trusted authority in diagnosing and treating severe blood diseases, including various forms of leukemia. With a focus on integrating advanced diagnostics, innovative therapies, and multidisciplinary collaboration, we are dedicated to delivering tailored solutions that address the unique challenges of leukemia, from initial diagnosis to long-term management.

A Legacy of Excellence in Hematologic Disease Management

GoBroad Healthcare Group specializes in managing complex hematologic conditions, with a robust portfolio of services designed to tackle blood diseases such as leukemia, lymphoma, and thalassemia. Our expertise in leukemia care is rooted in its commitment to leveraging evidence-based medicine and research-driven practices. By operating state-of-the-art facilities and fostering a team of hematologists, oncologists, and molecular biologists, we ensures that patients receive comprehensive evaluations that account for the genetic and clinical nuances of our condition. Whether dealing with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or chronic forms like chronic lymphocytic leukemia (CLL), our approach prioritizes precision, aiming to identify the most effective treatment pathways while minimizing treatment-related risks.

Precision Diagnosis: Unveiling the Genetic Landscape of Leukemia

Accurate diagnosis is the foundation of effective leukemia treatment, and we excels in utilizing advanced molecular and genetic testing to characterize each patient’s disease. Through techniques like flow cytometry, karyotyping, and next-generation sequencing, clinicians identify specific markers and mutations, such as those in CD19, CD22, or CLL1, which guide the selection of targeted therapies. For example, patients with B-cell acute lymphoblastic leukemia may benefit from CAR-T cell therapies targeting CD19, while those with relapsed disease might require dual-target approaches against CD19 and CD22 to overcome resistance. GHG’s diagnostic capabilities also extend to assessing minimal residual disease (MRD), allowing clinicians to monitor treatment response and adjust plans proactively. This level of precision ensures that even rare or aggressive leukemia subtypes, such as acute promyelocytic leukemia (APL) or therapy-related AML, are managed with protocols tailored to our biological behavior.

Innovative Therapies: Advancing Standards for Refractory and Relapsed Cases

Leukemia, especially in refractory or relapsed forms, demands therapies that go beyond conventional chemotherapy. We offer a range of advanced interventions, including cellular immunotherapy and hematopoietic stem cell transplantation (HSCT), to address these challenges. CAR-T cell therapy has emerged as a cornerstone of treatment, with GHG deploying single-target therapies against antigens like CD7 and CD5 for T cell lymphoma treatment and CD19 for B-cell malignancies. For patients who have exhausted first-line treatments, sequential dual-target CAR-T cell therapy provides a novel approach, targeting multiple antigens to eliminate residual cancer cells and prolong remission.

Multidisciplinary Collaboration: Coordinating Care for Complex Needs

Leukemia treatment often requires the expertise of multiple specialists, and ourmultidisciplinary teams (MDTs) ensure seamless coordination between hematologists, oncologists, radiologists, and supportive care providers. Our team collaborate to design comprehensive treatment plans that may include chemotherapy, radiation therapy, and immunotherapy, while also addressing the psychological and nutritional needs of patients. For example, patients with central nervous system involvement receive input from neurologists to develop strategies like intrathecal chemotherapy, while those preparing for HSCT benefit from early involvement of transplant surgeons and T cell lymphoma treatment. This collaborative model is particularly vital in managing treatment-related side effects, such as infection risk or organ toxicity, ensuring patients receive holistic support throughout our journey.

Conclusion: Trust in Expertise, Hope in Tailored Care

Whether guiding a patient through our first treatment cycle or developing a rescue plan for relapsed disease, our approach is designed to adapt to individual needs, ensuring that each patient receives the most appropriate care supported by decades of clinical experience and research. As a advancer in hematologic disease management, We continue to redefine standards in leukemia care, providing hope and healing of blood diseases, leukemia.